The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Open accessAbstract
Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety and efficacy data generated in Europe from usage of fumaric acid formulations in the latter disease constituted grounds to investigate their effects in MS patients. Dimethyl fumarate (DMF) was found to be the active principle in those formulations and in vitro studies have demonstrated that DMF has immune-modulatory properties exerted through abilities to divert cytokine production toward a Th2 profile, both on lymphocytes and microglial cells. More importantly, DMF was discovered to impact the anti-oxidative stress cell machinery promoting the transcription of genes downstream to the activation of the nuclear factor (erythroid derived 2)-like2 (NRF2). DMF exposure increases the cytosol concentrations of NRF2, which besides immune regulatory effects, has the potential for cytoprotection on glial cells, oligodendrocytes and neurons. Extensive and rigorous clinical trials have assessed the efficacy and safety of DMF at the dose of 240 mg twice and three times a day in relapsing-remitting MS patients during one phase IIb and two phase III trials. Robust, positive results were obtained across a number of clinical and paraclinical parameters. In one study (DEFINE), the relative reductions of the adjusted annualized relapse rate of the low and high dose regimens in comparison with placebo were 53% and 48%, respectively ( p < 0.001 for both comparisons). In the other trial (CONFIRM), DMF decreased the annualized relapse rate in comparison with placebo by 44% in the lower and by 51% in higher dosage group (also p < 0.001). The number and size of lesions as detected by magnetic resonance imaging were also significantly decreased in comparison with the patients receiving DMF at every dosage. Multiple post hoc and subgroup analyses corroborated the clinical data, rendering DMF an appealing medication whose potential for impacting the degenerative aspects of MS remains to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“In the end, the impact on T lymphocytes seems to be just a portion of the modifications induced by DMF, which influences several other cells, including macrophages, microglia, astrocytes and neurons [Moharregh-Khiabani et al. 2009; Linker et al. 2011].”
BackgroundOffen, D., Gilgun-Sherki, Y., & Melamed, E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0348-9 · Cited by 638
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Yang, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 482
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100977 · Cited by 352
Antipsoriatic effect of fumaric acid derivatives
Altmeyer, P. J., Mattlies, U., Pawlak, F., Hoffmann, K., Frosch, P. J., Ruppert, P., Wassilew, S. W., Horn, T., Kreysel, H. W., Lutz, G., et al. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70121-0 · Cited by 300
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72151 · Cited by 297
Schilling, S., Goelz, S., Linker, R., Luehder, F., & Gold, R. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03094.x · Cited by 271
de Jong, R., Bezemer, A. C., Zomerdijk, T. P. L., van de Pouw‐Kraan, T., Ottenhoff, T. H. M., & Nibbering, P. H. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260916 · Cited by 226
Schimrigk, S., Brune, N., Hellwig, K., Lukas, C., Bellenberg, B., Rieks, M., Hoffmann, V., Pöhlau, D., & Przuntek, H. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01292.x · Cited by 217
Hanson, J., Gille, A., Zwykiel, S., Lukasova, M., Clausen, B. E., Ahmed, K., Tunaru, S., Wirth, A., & Offermanns, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42273 · Cited by 197
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H., & Wattjes, M. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215357 · Cited by 185
Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Moharregh-Khiabani, D., Linker, R., Gold, R., & Stangel, M. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602788 · Cited by 139
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters
Werdenberg, D., Joshi, R., Wolffram, S., Merkle, H. P., & Langguth, P. (2003) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.364 · Cited by 136
Therapies for multiple sclerosis: translational achievements and outstanding needs
Haghikia, A., Hohlfeld, R., Gold, R., & Fugger, L. H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.004 · Cited by 126
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124 · cited 3×
“It has now undergone the most rigorous clinical testing for patients with MS and its safety has been established [Fox et al. 2014].”
BackgroundMethodResultInfluentialLitjens, N. H. R., Rademaker, M., Ravensbergen, B., Réa, D., van der Plas, M. J. A., Thio, B., Walding, A., van Dissel, J. T., & Nibbering, P. H. (2004) · European Journal of Immunology · doi:10.1002/eji.200324174 · Cited by 108
Gold, R., Phillips, J. T., Havrdová, E., Bar‐Or, A., Kappos, L., Kim, N., Thullen, T. D., Valencia, P., Oliva, L., Novas, M., et al. (2015) · Neurology and Therapy · doi:10.1007/s40120-015-0033-1 · Cited by 101
Manufacturer's Response to Case Reports of PML
Sweetser, M. T., Dawson, K. T., & Bozic, C. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300283 · Cited by 99
Dimethyl fumarate – only an anti‐psoriatic medication?
Meißner, M., Valesky, E. M., Kippenberger, S., & Kaufmann, R. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07996.x · Cited by 84
Hutchinson, M., Fox, R. J., Miller, D. H., Phillips, J. T., Kita, M., Havrdová, E., O'Gorman, J. T., Zhang, R., Novas, M., Viglietta, V., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6968-1 · Cited by 84
Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
Burness, C. B., & Deeks, E. D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0155-5 · Cited by 81
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
Arnold, D. L., Gold, R., Kappos, L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Yang, M., Zhang, R., Stephan, M., Sheikh, S. I., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7412-x · Cited by 75
Kappos, L., Gold, R., Arnold, D. L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Sarda, S. P., Agarwal, S., Zhang, A., Sheikh, S. I., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513507817 · Cited by 66
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdová, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Eraksoy, M., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511421054 · Cited by 65
Gold, R., Giovannoni, G., Phillips, J. T., Fox, R. J., Zhang, A., Meltzer, L. A., & Kurukulasuriya, N. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514537013 · Cited by 62
Dimethyl fumarate for multiple sclerosis
Papadopoulou, A., D’Souza, M., Kappos, L., & Yaldizli, Ö. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.534778 · Cited by 58
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55 · cited 2×
“…constitutes an essential element for it to be considered a suitable treatment option, and in the neurology clinical practice, the variability of the courses of MS demands decision making that involves computing risks and benefits [Bourdette and Whitham, 2010; Carrithers, 2014; Nicholas et al.”
BackgroundHavrdová, E., Hutchinson, M., Kurukulasuriya, N., Raghupathi, K., Sweetser, M. T., Dawson, K. T., & Gold, R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.826190 · Cited by 53
Kita, M., Fox, R. J., Phillips, J. T., Hutchinson, M., Havrdová, E., Sarda, S. P., Agarwal, S., Kong, J., Zhang, A., Viglietta, V., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513507818 · Cited by 50
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
Arnold, D. L., Gold, R., Kappos, L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Yang, M., Zhang, R., Stephan, M., Sheikh, S. I., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7504-7 · Cited by 42
Effects of monomethylfumarate on dendritic cell differentiation
Litjens, N. H. R., Rademaker, M., Ravensbergen, B., Thio, H. B., van Dissel, J. T., & Nibbering, P. H. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.07002.x · Cited by 41
Wilms, H., Arnold, P., Mojumder, D. K., DeToledo, J. C., & Lucius, R. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s35033 · Cited by 35
Straßburger-Krogias, K., Ellrichmann, G., Krogias, C., Altmeyer, P. J., Chan, A., & Gold, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614544466 · Cited by 35
Mode of action and clinical studies with fumarates in multiple sclerosis
Salmen, A., & Gold, R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.02.015 · Cited by 30
Racke, M. K., Nicholas, J. A., Boster, A. L., Imitola, J., & O’Connell, C. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50962 · Cited by 27
Kawalec, P., Mikrut, A., Wiśniewska, N., & Pilc, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140115214801 · Cited by 15
Immunotherapy and multiple sclerosis
BOURDETTE, D. N., & Whitham, R. H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1b36 · Cited by 7
From injection therapies to natalizumab: views on the treatment of multiple sclerosis
Bomprezzi, R., Okuda, D. T., Alderazi, Y. J., Stüve, O., & Frohman, E. M. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611431289 · Cited by 6
Self-citation
Cited by
Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2223-0 · Cited by 2,632
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
The multifaceted role of Nrf2 in mitochondrial function
Holmström, K. M., Kostov, R. V., & Dinkova-Kostova, A. T. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.10.002 · Cited by 368
Angelova, P. R., Esteras, N., & Abramov, A. Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21712 · Cited by 287
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Metadata
- Authors
- Bomprezzi, R.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2015-01
- Volume
- 8
- Issue
- 1
- Pages
- 20-30
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2094803175
- Cited by
- 301
- References
- 42
- FWCI
- 23.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.